Apimeds Pharmaceuticals US, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-20.2M | $-35.1M | $-1.2M | $-1.8M | $-2.7M | $-402.4K | $-311.6K | $-332.5K |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $4.7K | $20.0K | — | — | $232 | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-5.7M | $-2.1M | $-3.8M | $-1.7M | $-3.4M | $-20.3K | $-99.6K | $-186.8K |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $9.4K | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $1.5M | $490.6K | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $3.5M | $920.0K | $8.5M | $0 | $11.9M | $267.2K | — | — |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-5.7M | $-2.1M | — | — | — | — | — | — |